Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.

By David H. Barlow, J. Gorman, M. Shear, S. Woods. Journal of the American Medical Association (JAMA), 2000

888 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Experimental and Cognitive Psychology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/91a967ef77c78d76e9d96ad44104f76747a78d7f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. K. Ressler
2. L. Roemer
3. Michael Davis
4. Naomi A. Fineberg
5. Y. Leykin
6. M. Kozak
7. Robert J. DeRubeis
8. Vladan Starcevic

In Experimental and Cognitive Psychology

1. L. Roemer
2. S. Orsillo
3. Y. Leykin
4. Page L. Anderson
5. Robert J. DeRubeis
6. E. Foa
7. F. Gardner
8. D. Mennin

In Pharmacology

1. Y. Leykin
2. Robert J. DeRubeis

Citations in the corpus

• Allegiance in Psychotherapy Outcome Research: Separating Association From Bias (2009, methodology): “Several multisite trials (e.g., Barlow et al., 2000; Foa et al., 2005; Heimberg et al., 1998) have utilized adversarial collaboration, with one of the sites well-known for its psychotherapy, and another similarly well-known for its pharmacotherapeutic treatment.”
• Acceptance and mindfulness-based approaches to anxiety: Conceptualization and treatment. (2005, background): “The most recent data on the efficacy of PCT are the product of a multicenter clinical trial comparing PCT, imipramine (the pharmacological treatment of choice at the time the study was conducted), and their combination (Barlow et al., 2000).”
• Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. (2007, result): “It is important to note that many patients in standard clinical care also refuse or terminate treatment prematurely; moreover, the dropout rate in our study was similar to that found in other large randomized, controlled trials with similar designs (44).”
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision (2002, background): “Three studies did not show a difference between drugs and psychological therapies (Barlow et al. 2000; Cohen et al. 1984; Mavissakalian et al. 1983).”
• Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders (2014, background): “and imipramine [207,224,233-240] in panic disorder (Level 1).”
• Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. (2004, background): “In some cases, combining these modalities in traditional ways may even decrease the overall efficacy.(4,5) If the learning hypothesis is correct for some mental disorders, then another way to approach pharmacological treatment is to enhance the learning that occurs in psychotherapy.”